Clinical Trial Update: Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating the safety and efficacy of PRG-2302 for refractory or relapsed B-cell acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• PRG-2302

Snippet

Sponsor: Tan Jie | Conditions: Acute Lymphoblastic Leukemia | EARLY_Phase 1 | Status: RECRUITING